Biotech entity
World Health Organization is the most frequent co-covered peer, appearing in 3 of the 4 tracked stories. Across a 15-day span, the pace is roughly 1.9 stories per week. The busiest single day carried 2. pharma accounts for 3 of the 4 tracked stories, while 1 other category carries the remainder.
Last mentioned: Jul 12, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
World Health Organization is the most frequent co-covered peer, appearing in 3 of the 4 tracked stories. Across a 15-day span, the pace is roughly 1.9 stories per week. The busiest single day carried 2. pharma accounts for 3 of the 4 tracked stories, while 1 other category carries the remainder. Source depth averages 3.8 original sources per story, versus 5.3 across the same-window beat baseline. The 8 average consequence score is above the beat benchmark of 6.4 in the same window. Democratic Republic of Congo appears in 4 tracked Biotech stories published from June 28, 2026 through July 12, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 50 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Democratic Republic of Congo. Shared-story counts are live from our verified record — not editorial picks.
The Bundibugyo ebolavirus outbreak in Congo has no approved vaccine or treatment, creating a pressing unmet medical need. With 894 cases and over 200 deaths, the crisis could accelerate biopharma R&D for neglected filovirus strains.
75 healthcare workers infected with the Ebola Bundibugyo strain in DRC expose critical gaps in vaccine coverage and trial infrastructure, pressuring biopharma to accelerate strain-specific countermeasures.
Source: yahoo.com · medscape.com
With no approved therapies for the Bundibugyo Ebola strain and an outbreak surpassing 500 fatalities, two candidate drugs have begun a clinical trial, and a prophylactic agent trial is imminent. The collaborative effort signals a pivot toward rapid, integrated R&D for neglected filoviruses.
At least 30 deaths with Ebola symptoms in a crowded DRC camp highlight untreated spread and demand for rapid point-of-care diagnostics and expanded vaccine access. With 5 million displaced at risk, biopharma firms face calls to accelerate countermeasure deployment.
Source: tribune.com.pk · examiner.com.au
Democratic Republic of Congo is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
